NEW YORK (GenomeWeb News) – Lentigen and Dharmacon today said they plan to develop and manufacture lentiviral expression reagents to deliver short hairpin RNA expression vectors into cells using RNA interference-mediated gene silencing.
 
As part of the alliance Dharmacon will design reagents combined with Lentigen's high-titer LentiMax vector system to develop the lentiviral particles. Terms of the deal call for Lentigen to manufacture and Dharmacon to sell the resulting products.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.